MedTrace Logo

Measurements of Breast Tissue Optical Properties

NCT00540540 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-10-20

No results posted yet for this study

Summary

Approximately twelve percent of the women in the United States will develop breast cancer, the most common form of cancer affecting women, with 183,000 new cases projected for 1995. Despite the increasing incidence, the age-adjusted death rate from carcinoma has remained relatively stable. Although the reason for this has not yet been demonstrated, this stability may be a direct consequence of early detection and improved therapy. Screening mammography as an early detection technique has been shown to reduce mortality by 23%. Mammographic abnormalities that go on to biopsy show 24% being positive for malignancy with great variability (6-75%). Breast biopsy is an expensive procedure with the risks of anesthesia and surgery which may be obviated by more specific non-invasive testing.

Conditions

  • Accessory; Breast Tissue

Interventions

DEVICE

Diffuse Optical Spectroscopy

Breast properties scanning

Sponsors & Collaborators

  • University of California, San Diego

    collaborator OTHER

  • Beckman Laser Institute University of California Irvine

    collaborator OTHER

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Bruce J Tromberg, Ph.D · Beckman Laser Institute

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1995-12-31
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00540540 on ClinicalTrials.gov